ABCL386
Antibody medicine for oncology treatment
Other · OtherCompany source
Company profile
About AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Company description AbCellera official website
Mission. Our vision is to build a company that can repeatedly beat the odds to deliver these medicines. Creating medicines is the most important work we can do.
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at AbCellera?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Atopic Dermatitis
- Autoimmunity
- Inflammatory conditions
- Neurological diseases
- Oncology
- Vasomotor Symptoms (VMS)/menopause
Who it serves
- Biotechnology companies
- Pharmaceutical companies
- Venture capital firms
Deployment & integration
On Premise · Other deployment with recorded integration context.
Geographic context
MarketsCanada · Global · United States
Company sourceOfficial website
Company milestones
Platform expansion
Phase 1/2 trial initiated for ABCL635 (first-in-class NK3R antibody for VMS). Phase 1 trial initiated Q3 2025 for ABCL575 (atopic dermatitis). ABCL688 entered IND-enabling studies Q2 2025. Shifted strategic focus in 2023 from partnerships to advancing internal pipeline. Developed COVID-19 antibody medicines with Eli Lilly that reached clinic.
Partnerships
Recorded partners
- 40+ pharmaceutical and biotech partners
- Abdera
- Atlas Venture
- DARPA
- Denali
- Eli Lilly
- Empirico
- Versant Ventures
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
ABCL575
Investigative monoclonal antibody for moderate-to-severe atopic dermatitis
Other · OtherCompany source
ABCL635
First-in-class antibody medicine for non-hormonal treatment of vasomotor symptoms (hot flashes)
Other · OtherCompany source
ABCL688
Antibody medicine targeting complex membrane protein for autoimmunity treatment
Other · OtherCompany source
Antibody Discovery Platform
Integrated platform for discovering and developing antibody-based medicines from target to clinic
Platform · On PremiseCompany source
Complex Transmembrane Protein Platform
Platform for developing first-in-class antibodies against intractable transmembrane proteins
Platform · On PremiseCompany source
Pandemic Response Platform
Rapid antibody treatment platform for emerging viruses
Platform · On PremiseCompany source
T-Cell Engager Platform
Platform for designing T-cell engagers for hard-to-treat cancers
Platform · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Cattle antibodies identify a cross-serotype broadly neutralising foot-and-mouth disease virus epitope.NPJ vaccines · Apr 2, 2026
Fast and Accurate Charge State Deconvolution of Protein Mass Spectra.Analytical chemistry · Jul 22, 2025
The secretory pathway in Tetrahymena is organized for efficient constitutive secretion at ciliary pockets.iScience · Nov 15, 2024
Navigating prostate cancer screening in Canada for marginalized men through PSA screening and guidelines adherence A call to action for policymakers.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · Sep 1, 2024
Best Practices for Microbial Challenge In-Use Studies to Evaluate the Microbial Growth Potential of Parenteral Biological Products; Industry and Regulatory Considerations.PDA journal of pharmaceutical science and technology · Aug 23, 2024
Correction: annexin A5-DM1 protein-drug conjugate for the treatment of triple-negative breast cancer.Molecular biomedicine · Apr 2, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
100+ antibody drug programs started
Since 2015 across partnerships
16 candidates reached clinic
Across partnership portfolio
2M+ patients treated worldwide
With partner-developed medicines
Potent inhibition of T cell-mediated inflammatory pathways
ABCL575 preclinical studies
Extended in vivo half-life supporting less frequent dosing
ABCL575 vs current clinical-stage molecules
Abdera Therapeutics
Development of VHH antibody-based radiotherapeutics
Developed one of the first VHH antibody-based radiotherapeutics in clinic in just over 3 years
Denali Therapeutics
Accelerating discovery of antibody-based therapies for neurological diseases
Secured expanded access to industry-leading technology for antibody discovery
Eli Lilly
Rapid development of COVID-19 antibody treatments using pandemic response platform
2 million+ patients treated worldwide with antibody medicines developed through partnerships
Empirico
Translating genetically validated targets into antibody-based therapies
Extended competitive advantage in target discovery and validation with best-in-class antibodies
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from AbCellera
Recent articles published on AbCellera's official website.
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Read on AbCelleraAbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Read on AbCelleraAbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Read on AbCelleraAbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
Read on AbCelleraAbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
Read on AbCellera07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.